FIELD: medicine.
SUBSTANCE: invention concerns a method for detecting sensitivity of a biological sample containing human lung cancer cells, a combination of a epidermis growth factor receptor inhibitor and a chemotherapeutic agent, by analysing the biological sample for superexpression of phosphorylated ACT protein and phosphorylated MAPC protein.
EFFECT: extended range of methods for evaluating sensitivity to EGFR inhibitors therapy.
10 cl, 1 ex, 11 dwg, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC COMPOSITION FOR REDUCING RESISTANCE TO TYROSINE KINASE INHIBITORS | 2016 |
|
RU2735493C2 |
| SELECTION OF MEDICATIONS FOR LUNG CANCER THERAPY BY MEANS OF ANTIBODY-BASED MATRICES | 2008 |
|
RU2519647C2 |
| DEVICE AND METHOD FOR LEUKOCYTE AND CANCER CELL RECOVERY BY FILTRATION | 2012 |
|
RU2578848C2 |
| METHOD OF TREATING CANCER CARRYING EGFR MUTATIONS | 2007 |
|
RU2492864C2 |
| THERAPEUTIC, DIAGNOSTIC AND PROGNOSTIC METHODS FOR BLADDER CANCER | 2015 |
|
RU2739942C2 |
| COMPOSITIONS AND METHODS OF TREATING AND DIAGNOSING CANCER-RESISTANT CANCER | 2015 |
|
RU2710735C2 |
| THERAPY OF MALIGNANT TUMOR, RESISTANT TO PLATINUM-BASED MEDICATIONS | 2005 |
|
RU2403065C2 |
| METHODS OF PREDICTING RESPONSE OF TRIPLE NEGATIVE MAMMARY GLAND CANCER TO THERAPY | 2011 |
|
RU2558931C2 |
| COMBINED THERAPY BY USING ANTIANGIOGENIC AGENTS AND TNF-ALPHA | 2002 |
|
RU2316337C2 |
| TREATING PATIENTS DIAGNOSED WITH PANCREATIC DUCT ADENOCARCINOMA WITH USING EPIDERMAL GROWTH FACTOR (EGFR) RECEPTOR MONOCLONAL ANTIBODIES | 2016 |
|
RU2728571C2 |
